Belvedere Trading
CPRX

Belvedere Trading’s Catalyst Pharmaceutical CPRX Stock Holding History

Belvedere Trading’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-28,488
Closed -$160K – 508
2021
Q2 		$160K Buy
+28,488
New +$147K 0.01% 220

Other funds holding CPRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Belvedere Trading's CPRX Position: Q3 2021 in Review

Belvedere Trading sold out of Catalyst Pharmaceutical (CPRX) in Q3 2021, closing a stake of 28,488 shares — an estimated $160K sold.

Belvedere Trading first reported a position in CPRX in Q2 2021 and held it in 1 quarter. The position peaked at $160K in Q2 2021. 144 funds tracked by Wall St. Rank hold CPRX as of Q3 2021.

  • Belvedere Trading reported no remaining Catalyst Pharmaceutical position as of Q3 2021 after selling out during the quarter.
  • Belvedere Trading sold 28,488 Catalyst Pharmaceutical shares in Q3 2021, an estimated $160K.
  • Belvedere Trading first reported a position in Catalyst Pharmaceutical in Q2 2021 and held it in 1 quarter.
  • Belvedere Trading's Catalyst Pharmaceutical position peaked at $160K in Q2 2021.
  • 144 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2021.

Based on Belvedere Trading's 13F filing for Q3 2021, filed 19 Oct 2021.